Filing Flows › Evofem Biosciences (EVFM) › Q1 2025
Evofem Biosciences (EVFM) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Evofem Biosciences (EVFM) reported revenue of $845K for the first quarter 2025 (Q1 2025), -77% from a year earlier and -88% from the quarter before. Operating margin was 38.7%, net earnings $956K (113.1% of revenue).
Evofem Biosciences, Q1 2025: revenue $845K (-76% year over year), operating margin 38.7%, net earnings $956K, operating cash flow $560K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $845K | -88% | -77% |
| Operating profit | $327K | — | — |
| Net earnings | $956K | — | — |
| Operating cash flow | $560K | — | +355% |
What changed
Revenue was $845K in Q1 2025, down 77% year over year and down 88% from the previous quarter.
Operating profit was $327K, a 38.7% margin (up 117.6 points year over year). Total costs fell 92% while revenue fell 77%. Net earnings were $1.0M. The effective tax rate was 0.0%. Non-operating items added $629K, 66% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $560K (up 355% year over year), 59% of net earnings. Non-cash charges added back $229K of depreciation and amortization and $70K of share-based compensation. Working capital and other items used $695K.
Questions
What was Evofem Biosciences' revenue in the first quarter 2025?
Evofem Biosciences (EVFM) reported revenue of $845K for the first quarter 2025 (Q1 2025), -77% from a year earlier and -88% from the quarter before.
Was Evofem Biosciences profitable in the first quarter 2025?
Operating profit was $327K (38.7% of revenue) and net earnings $956K.
Source: Evofem Biosciences 10-Q on SEC EDGAR.